Australian Stock Report - Share Tips
Shares to buy : Nanosonics Limited (ASX: NAN)
share-tips
Publish date: Fri, 30 Aug 2019, 11:28 AM
share-tips
0 1,810
Our stock analysis blog provides information on stocks to watch and helps you figure out which are the best stock to buy. We use fundamental and technical analysis to identify the stocks tips that will supercharge your portfolio. We don't believe in choosing stock tips on rumours or hearsay. Our share tips use fundamental analysis, like price-to-equity ratios, cash flow analysis and net tangible assets, to identify the best share trading opportunities. We then use technical analysis, which is the study of price charts, to determine the best level to buy shares. We believe using the two school of investment analysis allows us the increase the chances of our share tips being successful.
About the Company
Nanosonics Limited (ASX:NAN) is an Australian listed producer and distributor of infection control solutions. In particular NAN’s Trophon product has proven to be an extremely effective sterilization method for ultrasound probes. Prior methods of sterilisation have proven to be ineffective at sterilising the probes, in particular in relation to Human Papillomavirous (HPV) which can lead to a number of cancers, including cervical cancer. As HPV is normally symptomless it often goes unnoticed and untreated indefinitely, but the disease is far from harmless, being responsible for 99.7% of all cervical cancers. Trophon EPR achieves disinfection of ultrasound probes via a unique patented technology that has a number of advantages over traditional techniques including being the only system currently proven to kill the cancer-causing HPV.
Our View
Nanosonics Limited (NAN) is an Australian listed producer and distributor of infection control solutions. In particular NAN’s Trophon product has proven to be an extremely effective sterilization method for ultrasound probes. Prior methods of sterilisation of such probes have proven to be ineffective at sterilising the probes, in particular in relation to Human Papillomavirus (HPV) which can lead to a number of cancers, including cervical cancer. As HPV is normally symptomless it often goes unnoticed and untreated indefinitely, but the disease is far from harmless, being responsible for 99.7% of all cervical cancers. Trophon EPR achieves disinfection of ultrasound probes via a unique patented technology that has a number of advantages over traditional techniques including being the only system currently proven to kill the cancer-causing HPV.
Uptake to date has been strong, as one would expect given the benefits to patients. The company estimates that the potential installed base of the product is 120,000 globally. Throughout 2016 NAN were able to grow the installed base to 10,000 globally, with 8,700 of these within North America. The North American installed base has grown rapidly since the establishment of direct sales operations in the second half of 2015, with installed units up 74% in 2016 and provides a good example as to how product rollouts are likely to occur in other territories. The company was able to grow margins in excess of sales growth in 2016 through the use of a direct sales operation in North America, and the increased sale of consumables and associated services that accompany the increased installed base.
Source: HALO Technologies – 10:30am AEDT, 30.08.2019
The post Shares to buy : Nanosonics Limited (ASX: NAN) appeared first on Australian Stock Report.
More articles on Australian Stock Report - Share Tips
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
1
2
CEO Morning Brief
Alibaba Aims to Raise US$5b in Dual Currency Bond Deal — Reuters
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
